Lupin to Focus on Biosimilars, Inhalation and Complex Generics to Improve Profitability, an Industrial Info Market Brief

Lupin Limited, India's third-largest drugmaker, said it will focus on execution of its complex generics pipeline, biosimilars and inhalation portfolio to improve profitability, as the company continues to face pricing pressure and regulatory challenges in the U.S. market.